Filing summary
Company-name mismatch: The request identifies Neurogene Inc., but the supplied Form 10-Q is for Neoleukin Therapeutics, Inc. (Nasdaq: NLTX). Confirm the intended issuer before relying on this summary.
Business context and reporting period
This unaudited Form 10-Q covers the quarter and nine months ended September 30, 2021. Neoleukin is a pre-revenue biopharmaceutical company developing de novo protein immunotherapies. Its lead candidate, NL-201, was in a Phase 1 trial for advanced solid tumors; management planned a Phase 1 trial in hematological malignancies in 2022.
Financial results and liquidity
| Metric | Q3 2021 | Q3 2020 | Nine months 2021 | Nine months 2020 |
|---|---|---|---|---|
| Research and development expense | $9.9 million | $6.2 million | $29.4 million | $16.6 million |
| General and administrative expense | $5.6 million | $3.9 million | $16.1 million | $12.4 million |
| Operating loss | $15.5 million | $2.3 million | $45.5 million | $21.1 million |
| Net loss | $15.4 million | $2.2 million | $45.5 million | $20.6 million |
| Net loss per share, basic and diluted | $0.28 | $0.04 | $0.83 | $0.41 |
The company reported no product revenue and has not achieved profitability. Gross margin is not applicable to the results presented. Operating cash use was $35.4 million for the first nine months of 2021, versus $15.3 million in 2020; capital expenditures were $2.9 million versus $1.6 million. Financing provided $0.6 million in 2021, compared with $75.8 million in 2020, which included a public offering.
At September 30, 2021, cash and cash equivalents were $154.9 million; working capital was $147.5 million; total assets were $175.9 million; total liabilities were $21.1 million; and stockholders’ equity was $154.9 million. Liabilities shown were primarily accounts payable and lease obligations; the filing presents no conventional borrowings. Management estimated cash would fund planned operations into the second half of 2023. On November 4, 2021, after quarter-end, the company entered an at-the-market agreement permitting up to $40 million of stock sales.
Changes versus the prior comparable period
- Q3 research and development expense rose 59%; nine-month expense rose 78%, primarily reflecting NL-201 clinical-trial work, personnel, other programs, and Seattle headquarters and laboratory costs.
- Q3 general and administrative expense increased 44%; nine-month expense increased 30%, mainly due to personnel and facility costs.
- Net losses increased substantially year over year. The 2020 comparison benefited from a $7.8 million gain on the sale of Aquinox Canada, recorded as a reduction of operating loss; there was no comparable gain in 2021.
- Cash and cash equivalents declined from $192.6 million at December 31, 2020 to $154.9 million at September 30, 2021.
Outlook, risks and notable items
- Management expects continued losses and significant spending on NL-201 and other research, and says further capital will be needed. The cash runway estimate depends on current plans and could change; financing may dilute shareholders or be unavailable on acceptable terms.
- The NL-201 Phase 1 trial was planned to enroll up to 120 patients and assess safety, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity. The filing emphasizes early-stage clinical, safety, regulatory, enrollment, manufacturing, and third-party execution risks.
- The company suspended plans in June 2021 to take its NL-CVX1 COVID-19 research program into clinical trials, citing changes in the therapeutic landscape and vaccine availability.
- COVID-19, including Delta-variant effects, could disrupt research, trials, suppliers, and financing. The company also depends on third-party manufacturers and research organizations and highlights uncertainty around its novel protein-design platform and intellectual-property protection.
- A March 2021 lease amendment increased future operating lease payments through 2026 by $1.9 million. Management reported no material legal proceedings and no off-balance-sheet arrangements.
Important facts for investors to verify
- Confirm the issuer: this filing is Neoleukin Therapeutics, not Neurogene Inc.
- Review NL-201 trial progress, enrollment, safety findings, and the status and timing of the proposed 2022 hematological-malignancy trial.
- Assess actual cash burn against management’s second-half-2023 runway estimate and monitor any sales under the $40 million ATM agreement.
- Verify the impact of continued R&D, facility costs, stock-based compensation, and potential dilution; 12.7 million pre-funded warrants were outstanding at September 30, 2021.